PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Stem cell scientist Irving Weissman joins OVP Venture Partners

Early-stage venture capital firm OVP Venture Partners has announced that stem cell scientist Irving L. Weissman will join its technical advisory group.

Early-stage venture capital firm OVP Venture Partners has announced that stem cell scientist Irving L. Weissman will join its technical advisory group.

The group consists of senior executives and technology leaders who provide input and insight on strategic market and technology directions relevant to OVP’s investment spaces and portfolio companies.

Weissman (pictured) co-discovered the mammalian and human hematopoietic stem cells and the human neural stem cell, and has formed three stem cell companies, SyStemix, StemCells and Cellerant.

He is a professor of cancer biology, pathology, and developmental biology at Stanford University and director of the Stanford Institute for Cancer/Stem Cell Biology and Medicine.

‘We’re delighted to have someone of Dr. Weissman’s caliber on hand to advise us on our current and potential investments in the life sciences,’ says OVP managing director Chad Waite. ‘We’ve been lucky enough to have Irv’s counsel on an informal basis in the past, and this appointment formalises that role.’
 
OVP currently has ten investments in life sciences and computational biology companies. The firm has over USD750m in capital under management and is currently investing its seventh fund.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured